Cargando…
Protein expression profiles indicative for drug resistance of non-small cell lung cancer
Data obtained from multiple sources indicate that no single mechanism can explain the resistance to chemotherapy exhibited by non-small cell lung carcinomas. The multi-factorial nature of drug resistance implies that the analysis of comprising expression profiles may predict drug resistance with hig...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364224/ https://www.ncbi.nlm.nih.gov/pubmed/12177790 http://dx.doi.org/10.1038/sj.bjc.6600463 |
_version_ | 1782153900320620544 |
---|---|
author | Volm, M Koomägi, R Mattern, J Efferth, T |
author_facet | Volm, M Koomägi, R Mattern, J Efferth, T |
author_sort | Volm, M |
collection | PubMed |
description | Data obtained from multiple sources indicate that no single mechanism can explain the resistance to chemotherapy exhibited by non-small cell lung carcinomas. The multi-factorial nature of drug resistance implies that the analysis of comprising expression profiles may predict drug resistance with higher accuracy than single gene or protein expression studies. Forty cellular parameters (drug resistance proteins, proliferative, apoptotic, and angiogenic factors, products of proto-oncogenes, and suppressor genes) were evaluated mainly by immunohistochemistry in specimens of primary non-small cell lung carcinoma of 94 patients and compared with the response of the tumours to doxorubicin in vitro. The protein expression profile of non-small cell lung carcinoma was determined by hierarchical cluster analysis and clustered image mapping. The cluster analysis revealed three different resistance profiles. The frequency of each profile was different (77, 14 and 9%, respectively). In the most frequent drug resistance profile, the resistance proteins P-glycoprotein/MDR1 (MDR1, ABCB1), thymidylate-synthetase, glutathione-S-transferase-π, metallothionein, O(6)-methylguanine-DNA-methyltransferase and major vault protein/lung resistance-related protein were up-regulated. Microvessel density, the angiogenic factor vascular endothelial growth factor and its receptor FLT1, and ECGF1 as well were down-regulated. In addition, the proliferative factors proliferating cell nuclear antigen and cyclin A were reduced compared to the sensitive non-small cell lung carcinoma. In this resistance profile, FOS was up-regulated and NM23 down-regulated. In the second profile, only three resistance proteins were increased (glutathione-S-transferase-π, O(6)-methylguanine-DNA-methyltransferase, major vault protein/lung resistance-related protein). The angiogenic factors were reduced. In the third profile, only five of the resistance factors were increased (MDR1, thymidylate-synthetase, glutathione-S-transferase-π, O(6)-methylguanine-DNA-methyltransferase, major vault protein/lung resistance-related protein). British Journal of Cancer (2002) 87, 251–257. doi:10.1038/sj.bjc.6600463 www.bjcancer.com © 2002 Cancer Research UK |
format | Text |
id | pubmed-2364224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23642242009-09-10 Protein expression profiles indicative for drug resistance of non-small cell lung cancer Volm, M Koomägi, R Mattern, J Efferth, T Br J Cancer Clinical Data obtained from multiple sources indicate that no single mechanism can explain the resistance to chemotherapy exhibited by non-small cell lung carcinomas. The multi-factorial nature of drug resistance implies that the analysis of comprising expression profiles may predict drug resistance with higher accuracy than single gene or protein expression studies. Forty cellular parameters (drug resistance proteins, proliferative, apoptotic, and angiogenic factors, products of proto-oncogenes, and suppressor genes) were evaluated mainly by immunohistochemistry in specimens of primary non-small cell lung carcinoma of 94 patients and compared with the response of the tumours to doxorubicin in vitro. The protein expression profile of non-small cell lung carcinoma was determined by hierarchical cluster analysis and clustered image mapping. The cluster analysis revealed three different resistance profiles. The frequency of each profile was different (77, 14 and 9%, respectively). In the most frequent drug resistance profile, the resistance proteins P-glycoprotein/MDR1 (MDR1, ABCB1), thymidylate-synthetase, glutathione-S-transferase-π, metallothionein, O(6)-methylguanine-DNA-methyltransferase and major vault protein/lung resistance-related protein were up-regulated. Microvessel density, the angiogenic factor vascular endothelial growth factor and its receptor FLT1, and ECGF1 as well were down-regulated. In addition, the proliferative factors proliferating cell nuclear antigen and cyclin A were reduced compared to the sensitive non-small cell lung carcinoma. In this resistance profile, FOS was up-regulated and NM23 down-regulated. In the second profile, only three resistance proteins were increased (glutathione-S-transferase-π, O(6)-methylguanine-DNA-methyltransferase, major vault protein/lung resistance-related protein). The angiogenic factors were reduced. In the third profile, only five of the resistance factors were increased (MDR1, thymidylate-synthetase, glutathione-S-transferase-π, O(6)-methylguanine-DNA-methyltransferase, major vault protein/lung resistance-related protein). British Journal of Cancer (2002) 87, 251–257. doi:10.1038/sj.bjc.6600463 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-07-29 2002-08-01 /pmc/articles/PMC2364224/ /pubmed/12177790 http://dx.doi.org/10.1038/sj.bjc.6600463 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Volm, M Koomägi, R Mattern, J Efferth, T Protein expression profiles indicative for drug resistance of non-small cell lung cancer |
title | Protein expression profiles indicative for drug resistance of non-small cell lung cancer |
title_full | Protein expression profiles indicative for drug resistance of non-small cell lung cancer |
title_fullStr | Protein expression profiles indicative for drug resistance of non-small cell lung cancer |
title_full_unstemmed | Protein expression profiles indicative for drug resistance of non-small cell lung cancer |
title_short | Protein expression profiles indicative for drug resistance of non-small cell lung cancer |
title_sort | protein expression profiles indicative for drug resistance of non-small cell lung cancer |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364224/ https://www.ncbi.nlm.nih.gov/pubmed/12177790 http://dx.doi.org/10.1038/sj.bjc.6600463 |
work_keys_str_mv | AT volmm proteinexpressionprofilesindicativefordrugresistanceofnonsmallcelllungcancer AT koomagir proteinexpressionprofilesindicativefordrugresistanceofnonsmallcelllungcancer AT matternj proteinexpressionprofilesindicativefordrugresistanceofnonsmallcelllungcancer AT effertht proteinexpressionprofilesindicativefordrugresistanceofnonsmallcelllungcancer |